Table 5 Hazard ratios and 95% confidence intervals of baseline low density lipoprotein cholesterol categories for all-cause mortality by sub-analysis

 Male (n = 1610)

2.80 (1.53–5.14)

1.84 (1.05–3.22)

0.98 (0.58–1.66)

<  0.001

0.039

 Female (n = 2074)

1.42 (0.42–4.74)

1.41 (0.73–2.70)

1.44 (0.94–2.19)

0.407

  < 25 kg/m² (n = 2681)

2.43 (1.46–4.05)

1.66 (1.07–2.58)

1.02 (0.70–1.48)

<  0.001

0.261

  ≥ 25 kg/m² (n = 1003)

2.36 (0.62–9.04)

1.46 (0.54–3.94)

1.89 (0.94–3.79)

0.308

 No (n = 3389)

2.63 (1.59–4.35)

1.62 (1.04–2.50)

1.15 (0.81–1.64)

<  0.001

0.907

 Yes (n = 295)

1.64 (0.39–6.93)

3.03 (1.03–8.84)

1.41 (0.52–3.82)

0.099

 No (n = 1583)

3.19 (1.35–7.56)

1.71 (0.80–3.66)

1.32 (0.71–2.45)

0.044

0.705

 Yes (n = 2101)

2.35 (1.33–4.16)

1.80 (1.13–2.88)

1.16 (0.79–1.70)

0.002

Lipid-lowering medication

 No (n = 3327)

2.75 (1.66–4.55)

2.06 (1.35–3.14)

1.31 (0.92–1.86)

<  0.001

0.379

 Yes (n = 357)

3.74 (0.91–15.4)

0.31 (0.08–1.17)

0.49 (0.19–1.28)

Diabetes

 No (n = 3334)

3.32 (2.00–5.52)

1.85 (1.19–2.86)

1.21 (0.84–1.75)

<  0.001

 Yes (n = 350)

0.78 (0.19–3.17)

1.21 (0.45–3.24)

Chronic kidney disease

 No (n = 3310)

1.92 (1.11–3.32)

1.48 (0.96–2.28)

1.04 (0.73–1.47)

0.017

 Yes (n = 374)

8.69 (2.77–27.3)

4.89 (1.62–14.7)

Time to death

  < 1095 days (n = 73)

Not examined

Not examined

Not examined

–

Not examined

  ≥ 1095 days (n = 3611)

2.68 (1.67–4.28)

1.74 (1.17–2.59)

1.20 (0.86–1.66)

<  0.001